NCT02992522 2025-09-09Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin LymphomaOhio State University Comprehensive Cancer CenterPhase 1 Active not recruiting22 enrolled